Last reviewed · How we verify
KX-826 0.5% BID
At a glance
| Generic name | KX-826 0.5% BID |
|---|---|
| Sponsor | Suzhou Kintor Pharmaceutical Inc, |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia (PHASE2, PHASE3)
- Phase III Study of KX-826 With Adult Male Patients With AGA (PHASE3)
- Phase II Study Evaluating the Efficacy and Safety of KX-826 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |